SC
CCXI

Sarissa Consulting’s ChemoCentryx, Inc. CCXI Stock Holding History

Sarissa Consulting’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$413K Buy
+8,000
New +$331K 0.43% 45

Other funds holding CCXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Sarissa Consulting's CCXI Position: Q3 2022 in Review

Sarissa Consulting opened a new position in ChemoCentryx, Inc. (CCXI) in Q3 2022: 8,000 shares worth $413K. The stake represents 0.43% of the portfolio and ranks #45 among its holdings.

217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

  • Sarissa Consulting held 8,000 shares of ChemoCentryx, Inc. worth $413K as of Q3 2022.
  • ChemoCentryx, Inc. was a new Sarissa Consulting position in Q3 2022.
  • ChemoCentryx, Inc. made up 0.43% of Sarissa Consulting's portfolio in Q3 2022, its #45 holding.
  • 217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Sarissa Consulting's 13F filing for Q3 2022, filed 14 Nov 2022.